down arrow

Aldeyra Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US01438T1060
USD
2.23
0.42 (23.2%)

Mar 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.822.32

52 Week

1.076.81
Valuation
Technical
Day's Volume

CASH

7.07 M

Shareholding (Dec 2025)

FII

3.76%

Held by 45 FIIs

DII

75.78%

Held by 21 DIIs

Promoter

4.76%

How big is Aldeyra Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Aldeyra Therapeutics, Inc. has a market capitalization of 185.08 million and reported net sales of 0.00 million with a net profit of -57.70 million over the last four quarters. Shareholder's funds were 71.00 million, and total assets were 104.61 million.

As of Jun 18, Aldeyra Therapeutics, Inc. has a market capitalization of 185.08 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -57.70 million during the same period.<BR><BR>As of Dec 24, the shareholder's funds amounted to 71.00 million, while total assets were reported at 104.61 million.

View full answer

What does Aldeyra Therapeutics, Inc. do?

22-Jun-2025

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for diseases associated with high aldehyde levels. It has a market cap of $185.08 million and reported a net profit loss of $10 million as of March 2025.

Overview: <BR>Aldeyra Therapeutics, Inc. is a biotechnology company focused on the identification and development of treatments for diseases related to high levels of aldehydes, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 185.08 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.17 <BR>Return on Equity: -90.72% <BR>Price to Book: 2.91<BR><BR>Contact Details: <BR>Address: 131 Hartwell Ave Ste 320, LEXINGTON MA: 02421-3105 <BR>Tel: ['1 781 7614904', '1 857 3832409'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.aldeyra.com/

View full answer

Who are in the management team of Aldeyra Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Aldeyra Therapeutics, Inc. includes Dr. Richard Douglas (Independent Chairman), Dr. Todd Brady (CEO), and several independent directors: Dr. Ben Bronstein, Mr. Martin Joyce, Ms. Nancy Miller-rich, Dr. Gary Phillips, and Mr. Jesse Treu.

As of March 2022, the management team of Aldeyra Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Richard Douglas, Independent Chairman of the Board<BR>- Dr. Todd Brady, President, Chief Executive Officer, Director<BR>- Dr. Ben Bronstein, Independent Director<BR>- Mr. Martin Joyce, Independent Director<BR>- Ms. Nancy Miller-rich, Independent Director<BR>- Dr. Gary Phillips, Independent Director<BR>- Mr. Jesse Treu, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors.

View full answer

Is Aldeyra Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 20, 2025, Aldeyra Therapeutics, Inc. shows a bullish trend with strong upward momentum indicated by the MACD and KST, despite mixed signals from Dow Theory and OBV, and has underperformed the S&P 500 over the past year and five years.

As of 20 August 2025, the technical trend for Aldeyra Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the KST is also bullish on both weekly and monthly time frames, indicating strong upward momentum. However, the weekly Dow Theory shows a mildly bearish stance, and the OBV is mildly bearish on the weekly but bullish on the monthly, suggesting some mixed signals. The moving averages are mildly bullish on the daily timeframe. <BR><BR>In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -14.65% compared to the S&P 500's 17.14%, and a 5-year return of -32.57% versus the S&P 500's 96.61%. Overall, the current stance is bullish, but the strength is tempered by some conflicting indicators.

View full answer

Compare Aldeyra Therapeutics, Inc. with Similar Stocks

Lyell Immunopharma, Inc.Edgewise Therapeutics, Inc.Scholar Rock Holding Corp.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 255 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.21

stock-summary
Return on Equity

-87.71%

stock-summary
Price to Book

5.17

Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-55.84%
0%
-55.84%
6 Months
-56.36%
0%
-56.36%
1 Year
-66.11%
0%
-66.11%
2 Years
-23.1%
0%
-23.1%
3 Years
-75.39%
0%
-75.39%
4 Years
-52.95%
0%
-52.95%
5 Years
-80.59%
0%
-80.59%

Aldeyra Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-4.13%
EBIT to Interest (avg)
-28.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
76.49%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.17
EV to EBIT
-4.31
EV to EBITDA
-4.34
EV to Capital Employed
-18.40
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-87.71%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 31 Schemes (15.68%)

Foreign Institutions

Held by 45 Foreign Institutions (3.76%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 58.86% vs -229.17% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.60",
          "val2": "-16.50",
          "chgp": "60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.50",
          "val2": "-15.80",
          "chgp": "58.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 39.53% vs -49.07% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-35.00",
          "val2": "-59.90",
          "chgp": "41.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "1.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-33.80",
          "val2": "-55.90",
          "chgp": "39.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.60
-16.50
60.00%
Interest
0.50
0.50
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.50
-15.80
58.86%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 58.86% vs -229.17% in Dec 2024

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-35.00
-59.90
41.57%
Interest
1.90
1.90
Exceptional Items
0.00
0.00
Consolidate Net Profit
-33.80
-55.90
39.53%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 39.53% vs -49.07% in Dec 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Aldeyra Therapeutics, Inc. stock-summary
stock-summary
Aldeyra Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
Company Coordinates stock-summary
Company Details
131 Hartwell Ave Ste 320 , LEXINGTON MA : 02421-3105
stock-summary
Tel: 1 781 76149041 857 3832409
stock-summary
https://www.aldeyra.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."